BSBryan Szeglin

Bryan Szeglin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bryan Szeglin has a total of 204 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Malignant Ascites Harbor Immune Niche with IL10-Enriched Effector Dysfunction and Persistent Cancer-Binding IgG

    by Elana R. Shaw, Alexei G. Hernandez, Linda Huang, Bryan C. Szeglin, Yuqian Wang, Carolyn M. Merwanji, Rosela Golloshi, Matthew Dunworth, Shannon N. Radomski, Charles Lim, et al.

    Malignant ascites provide a window into cancer–immune interactions in the peritoneal cavity. Using cytometry by time of flight, we analyzed ascitic immune cells collected from patients with advanced gastrointestinal cancers and nonmalignant forms of hepatitis (NMH) and healthy-control peripheral blood mononuclear cells (HC PBMC). Compositionally, ascitic immune cells shared a myeloid-rich, B cell– and naïve T cell–low signature relative to HC PBMCs. Underneath the shared ascitic compositional signature, three major functional immunophenotypes emerged in response to exogenous stimulation along a suppressive to cytotoxic axis, aligning with Luminex measurements of ascitic cytokine levels: IL10-enriched, nonpolarized, and granzyme B (GZMB)–enriched. In our cohort, the IL10-enriched functional immunophenotype was exclusive to samples from patients with cancer whereas the GZMB-enriched response was dominated by NMH samples. Ascites from patients with pancreatic ductal adenocarcinoma (PDAC) contained a persistent anticancer humoral response characterized by IgG that bound to autologous ascitic PDAC cells and multiple allogeneic PDAC cell lines. Significance: During the escape phase of cancer immunoediting, humoral immune recognition of cancer cells may persist within malignant ascites despite impaired cellular cytotoxic immunity in patients with advanced gastrointestinal cancers.

  • Short- Versus Long-Course Radiation in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Propensity-Matched National Cancer Database Analysis

    by Bryan Szeglin, Michael S. Consul, Megan C. Breckheimer, James J. Whitbread, Miloslawa Stem, Alodia A. Gabre-Kidan, Andrea C. Bafford, John Migaly

    BACKGROUND: Locally advanced rectal cancer is treated with total neoadjuvant therapy, which consists of neoadjuvant chemotherapy, radiation, and surgery. The comparative efficacy of long- and short-course radiotherapy within total neoadjuvant therapy remains uncertain. OBJECTIVE: Compare overall survival and pathological outcomes between patients treated with long- or short-course radiation as components of total neoadjuvant therapy. DESIGN: Retrospective cohort study. SETTINGS: National Cancer Database, 2018 to 2023. PATIENTS: Adults with clinical stage II or III rectal adenocarcinoma treated with neoadjuvant chemotherapy and radiation followed by radical surgical resection. MAIN OUTCOME MEASURES: Overall survival and pathological outcomes in a propensity score–matched cohort comparing long- and short-course radiation. RESULTS: A total of 12,462 patients met inclusion criteria; 10,740 patients (86.2%) received long-course radiation, and 1722 patients (13.8%) received short-course radiation. After 1:1 propensity score matching, 1721 patients per group were identified. Overall survival at 48 months did not differ (log-rank, p = 0.397). There were no differences in pathological complete response rate, pathological tumor stage, tumor downstaging, or pathological nodal stage. The long-course radiotherapy group had higher nodal downstaging (66.5% vs 62.7%; p = 0.023) and a nonsignificant trend toward lower nodal disease (N0 73.9% vs 70.7%, N1 21.5% vs 23.3%, and N2 4.6 vs 6.0%, respectively; p = 0.062). LIMITATIONS: Residual confounding from unmeasured clinical and treatment details is possible. This cohort was restricted to patients who underwent resection. CONCLUSIONS: Among patients with locally advanced rectal cancer who are treated with total neoadjuvant therapy and radical resection, long- and short-course radiotherapy had similar overall survival, but long-course radiotherapy patients had higher rates of nodal downstaging. These findings support the use of either long- or short-course radiotherapy regimens when planned resection is intended, but the clinical significance of differences in nodal downstaging remains uncertain. See Video Abstract. RADIOTERAPIA DE CORTA DURACIÓN versus DE LARGA DURACIÓN EN LA TERAPIA NEOADYUVANTE TOTAL PARA EL CÁNCER DE RECTO LOCALMENTE AVANZADO: UN ANÁLISIS DE LA BASE DE DATOS NACIONAL SOBRE CÁNCER CON EMPAREJAMIENTO POR PROPENSIÓN: ANTECEDENTES: El cáncer de recto localmente avanzado se trata con terapia neoadyuvante total, que consiste en quimioterapia neoadyuvante, radioterapia y cirugía. La eficacia comparativa de la radioterapia de ciclo largo y corto dentro de la terapia neoadyuvante total sigue siendo incierta. OBJETIVO: Comparar la supervivencia global y los resultados patológicos entre pacientes tratados con radioterapia de ciclo largo o corto como componentes de la terapia neoadyuvante total. DISEÑO: Estudio de cohorte retrospectivo. ÁMBITO: Base de datos nacional de cáncer, 2018 a 2023. PACIENTES: Adultos con adenocarcinoma de recto en estadio clínico II o III tratados con quimioterapia neoadyuvante y radioterapia seguida de resección quirúrgica radical. PRINCIPALES MEDIDAS DE RESULTADO: Supervivencia global y resultados patológicos en una cohorte emparejada por puntuación de propensión que compara la radioterapia de ciclo largo y corto. RESULTADOS: Un total de 12.462 pacientes cumplieron los criterios de inclusión; 10.740 (86,2 %) recibieron radioterapia de ciclo largo y 1.722 (13,8 %) recibieron radioterapia de ciclo corto. Tras el emparejamiento por puntuación de propensión 1:1, se identificaron 1.721 pacientes por grupo. La supervivencia global a los 48 meses no presentó diferencias significativas (log rank p = 0,397). No se observaron diferencias en la tasa de respuesta patológica completa, el estadio tumoral patológico, la reducción del estadio tumoral ni el estadio ganglionar patológico. El grupo de radioterapia de ciclo largo presentó una mayor reducción del estadio ganglionar (66,5 % frente a 62,7 %, p = 0,023) y una tendencia no significativa hacia una menor afectación ganglionar (N0 73,9% frente a 70,7 %, N1 21,5 % frente a 23,3 % y N2 4,6 % frente a 6,0 %, respectivamente, p = 0,062). LIMITACIONES: Es posible que exista confusión residual debido a detalles clínicos y de tratamiento no medidos. Esta cohorte se limitó a pacientes sometidos a resección. CONCLUSIONES: Entre los pacientes con cáncer de recto localmente avanzado tratados con terapia neoadyuvante total y resección radical, la radioterapia de ciclo largo y corto tuvo una supervivencia global similar, pero los pacientes con radioterapia de ciclo largo presentaron mayores tasas de reducción del estadio ganglionar. Estos hallazgos respaldan el uso de regímenes de radioterapia de ciclo largo o corto cuando se planifica una resección, pero la relevancia clínica de las diferencias en la reducción del estadio ganglionar sigue siendo incierta. (AI-generated translated )

  • Open Access

    Pioneering use of genetic analysis for CDH1 to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer

    by Farzad Mokhtari-Esbuie, Bryan Szeglin, Mohsen Rouhani Ravari, Mark Duncan, John W Harmon

    Worldwide, gastric cancer results in significant morbidity and mortality. Ten per cent of patients with gastric cancer have a strong family history of the disease. CDH1 (E-cadherin) has been identified as a key gene whose mutation leads to hereditary diffuse gastric cancer. We overviewed 33 articles with prophylactic total gastrectomy and assessed the outcomes and benefits. Families with mutations in CDH1 may benefit from early prophylactic total gastrectomy. Dr Mark Duncan has applied his experience as a high-volume gastric cancer surgeon to treat not only individual patients, but several generations of patients within a family. This use of prophylactic total gastrectomy is well tolerated by patients and prevents the future development of gastric cancer.


  • Open Access

    Data from Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids

    by Kuo-Shun Hsu, Mohammad Adileh, Maria Laura Martin, Vladimir Makarov, Jiapeng Chen, Chao Wu, Sahra Bodo, Stefan Klingler, Charles-Etienne Gabriel Sauvé, Bryan C. Szeglin, et al.

    Identifying colorectal cancer patient populations responsive to chemotherapy or chemoradiation therapy before surgery remains a challenge. Recently validated mouse protocols for organoid irradiation employ the single hit multi-target (SHMT) algorithm, which yields a single value, the D0, as a measure of inherent tissue radiosensitivity. Here, we translate these protocols to human tissue to evaluate radioresponsiveness of patient-derived organoids (PDO) generated from normal human intestines and rectal tumors of patients undergoing neoadjuvant therapy. While PDOs from adenomas with a logarithmically expanded Lgr5+ intestinal stem cell population retain the radioresistant phenotype of normal colorectal PDOs, malignant transformation yields PDOs from a large patient subpopulation displaying marked radiosensitivity due to reduced homologous recombination–mediated DNA repair. A proof-of-principle pilot clinical trial demonstrated that rectal cancer patient responses to neoadjuvant chemoradiation, including complete response, correlate closely with their PDO D0 values. Overall, upon transformation to colorectal adenocarcinoma, broad radiation sensitivity occurs in a large subset of patients that can be identified using SHMT analysis of PDO radiation responses.Significance:Analysis of inherent tissue radiosensitivity of patient-derived organoids may provide a readout predictive of neoadjuvant therapy response to radiation in rectal cancer, potentially allowing pretreatment stratification of patients likely to benefit from this approach.

  • Open Access

    Supplementary Data from Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy

    by Andrea Cercek, Gustavo Dos Santos Fernandes, Campbell S. Roxburgh, Karuna Ganesh, Shu Ng, Francisco Sanchez-Vega, Rona Yaeger, Neil H. Segal, Diane L. Reidy-Lagunes, Anna M. Varghese, et al.

    Supplementary Methods and Supplementary Table 1

  • Open Access

    Supplementary Figure 2 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance

    by Isaac Wasserman, Lik Hang Lee, Shuji Ogino, Michael R. Marco, Chao Wu, Xi Chen, Jashodeep Datta, Eran Sadot, Bryan Szeglin, Jose G. Guillem, et al.

    Kaplan-Meier graph with number of subjects at risk comparing (a) SMAD4, (b) TIL, and (c) PLA status, separately, as well as (d) SMAD4 and TIL, and (e) SMAD4 and PLA, together, with recurrence-free survival (RFS) among only the MMR-proficient patients.

  • Open Access

    Supplementary Figure 3 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance

    by Isaac Wasserman, Lik Hang Lee, Shuji Ogino, Michael R. Marco, Chao Wu, Xi Chen, Jashodeep Datta, Eran Sadot, Bryan Szeglin, Jose G. Guillem, et al.

    Kaplan-Meier graphs in the validation cohort with number of subjects at risk showing colorectal cancer-specific survival according to SMAD4 status.

  • Open Access

    Supplementary Figure 1 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance

    by Isaac Wasserman, Lik Hang Lee, Shuji Ogino, Michael R. Marco, Chao Wu, Xi Chen, Jashodeep Datta, Eran Sadot, Bryan Szeglin, Jose G. Guillem, et al.

    Kaplan-Meier graphs with number of subjects at risk comparing recurrence-free survival (RFS) by (a) TIL status, or (b) PLA status, with arrows indicating patients whose tumors were also SMAD4 loss.

  • Open Access

    Supplementary Table 3 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance

    by Isaac Wasserman, Lik Hang Lee, Shuji Ogino, Michael R. Marco, Chao Wu, Xi Chen, Jashodeep Datta, Eran Sadot, Bryan Szeglin, Jose G. Guillem, et al.

    Distribution of colorectal cancer cases according to SMAD4 expression status and immune response to the tumor in validation cohort

  • Open Access

    Supplementary Figure Legends from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance

    by Isaac Wasserman, Lik Hang Lee, Shuji Ogino, Michael R. Marco, Chao Wu, Xi Chen, Jashodeep Datta, Eran Sadot, Bryan Szeglin, Jose G. Guillem, et al.